RxDoctor Payments Data

Mary Gibbons, PA

Medical · Pittsburgh, PANPI 1578061313

Payments from drug & device makers

$7,193in general payments, 2019–2025

Across 302 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$999
  • E.r. Squibb & Sons, L.L.C.$737
  • AstraZeneca$688
  • Boehringer Ingelheim$618
  • Johnson & Johnson$441
  • plus $2K from 17 others
$200in research payments, 2019–2025

Across 2 payments — averaging $100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$200

What the payments were for

  • Food & beverage$7,179100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,193 in reported general payments places this provider in the 90th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,238
Medicare patients
45
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$229,825
Repatha SureclickEvolocumab108$87,113
EntrestoSacubitril/Valsartan111$80,211
BrilintaTicagrelor159$78,588
JardianceEmpagliflozin81$71,443
XareltoRivaroxaban21$22,889
Praluent PenAlirocumab40$19,026
Repatha SyringeEvolocumab12$6,370
Ranolazine ErRanolazine107$6,355
Diltiazem 12hr ErDiltiazem Hcl15$4,896
Atorvastatin Calcium446$3,919
Metoprolol Succinate400$3,688
Rosuvastatin Calcium182$2,418
ClopidogrelClopidogrel Bisulfate275$2,320
Bumetanide83$1,951

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$215$229,825280 claims
NovartisEntresto$428$80,211111 claims
AstraZenecaBrilinta$688$78,588159 claims
Boehringer IngelheimJardiance$618$71,44381 claims
Johnson & JohnsonXarelto$441$22,88921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →